On the other hand, studies that compared Osimertinib plus bevacizumab against Osimertinib monotherapy failed to demonstrate improved PFS in patients with NSCLC harboring EGFR mutations [15,16,17]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.